AbbVie signs multi-year AI drug discovery collaboration with Iambic
AbbVie announced a multi-year collaboration with Iambic to use its AI platform, including Enchant v3, to accelerate small-molecule discovery across immunology, neuroscience and oncology. Iambic will receive an upfront payment, milestones and tiered royalties.
AbbVie said it has entered a multi-year collaboration with Iambic to use Iambic's AI platform, including Enchant v3, to speed small-molecule discovery across immunology, neuroscience and oncology. Iambic will receive an upfront payment, milestones and tiered royalties.